Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | The FDA approval clears Welireg's use with Keytruda in earlier-stage kidney cancer, following its 2023 solo nod for advanced disease.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
Merck wins FDA approval for Welireg+Keytruda in adjuvant clear cell kidney cancer, after study showed a 28% risk reduction vs.…
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG®…
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a…
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s…
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
